Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.
about
Plant-based solutions for veterinary immunotherapeutics and prophylacticsB-Cell Epitopes in GroEL of Francisella tularensisNeonatal Vaccination: Challenges and Intervention StrategiesProteomics-identified Bvg-activated autotransporters protect against bordetella pertussis in a mouse model.Review of the neutrophil response to Bordetella pertussis infection.The Bordetella adenylate cyclase repeat-in-toxin (RTX) domain is immunodominant and elicits neutralizing antibodies.Perspectives for clinical use of engineered human host defense antimicrobial peptidesMaternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.Canadian Adjuvant Initiative Workshop, March 26-27, 2013--Ottawa, CanadaVaccine Potentiation by Combination AdjuvantsMechanism of Mitochondrial Transcription Factor A Attenuation of CpG-Induced Antibody Production.Strategies and new developments to control pertussis, an actual health problemImmune modulation by multifaceted cationic host defense (antimicrobial) peptides.Mouse and pig models for studies of natural and vaccine-induced immunity to Bordetella pertussis.Possible options for new pertussis vaccines.Management and prevention of pertussis infection in neonates.Large animal models for vaccine development and testing.CD71+ erythroid suppressor cells impair adaptive immunity against Bordetella pertussis.What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.Protection of neonates and infants by maternal immunization.Pertussis: pertussis control strategies and the options for improving current vaccines.Effect of age and maternal antibodies on the systemic and mucosal immune response after neonatal immunization in a porcine model.The pertussis problem.Pertussis: A Global Perspective.
P2860
Q27000876-1425C376-9B9D-4CE7-90B3-816B4730CC75Q27684471-03162BF8-1AC1-4BF7-9578-D67006C1D2B2Q28066069-CDD1651D-B113-485D-A225-3E92C6A2ED56Q30208978-7BB21772-E423-4BF0-9E90-EDD954263E61Q30278579-193F5A4C-5309-48DB-B929-306A0AD37F1DQ30301113-B2A699CC-4EA2-4765-B9FA-9A66AEA52886Q33700825-5DA39C40-8901-4A6C-B734-D09F809B8B79Q34193265-6073658C-595A-4882-B4EE-4BF31C1649ECQ34290818-416ADDB1-1E72-4A51-AED2-F68E9D2E0D7FQ35826767-1FCA37F4-4EB4-4083-BB6A-DFDB098A7648Q36046749-F0778015-3D89-4486-B933-317357AA97A6Q36226470-F376DD32-702F-413C-B34E-0757CC85F681Q38162670-1E5320B3-316F-44D8-B48F-B4EB91F5BDD1Q38195758-25CB4FA6-3595-4FA2-AA78-8CA28618CE15Q38195759-B9814E4C-5F4F-4969-B7FE-D31CB6A0984BQ38265131-420D14E9-5BD6-42A2-AB38-9DF175B43EC6Q38492768-C93E3EBF-1B33-4FE5-A302-4A1EF1EDED78Q38629725-739F9708-7AB8-41B1-BD85-5AF7973C3982Q40295958-4531CB93-4970-49A5-A7F4-CAB6BE38E792Q40650298-CAAFCF32-8283-4ED1-A4DF-F188E21A5512Q44324857-26A66923-A214-4017-AA85-0E43FBBC554AQ51728533-F0464B11-FBCF-48E3-B712-159D9A61A628Q54406017-B9C05885-76CC-4251-95DE-67D1D941126FQ55254475-846E989A-29D0-4F09-97D0-A84068C3B96B
P2860
Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Novel vaccine formulations aga ...... esence of maternal antibodies.
@en
Novel vaccine formulations aga ...... esence of maternal antibodies.
@nl
type
label
Novel vaccine formulations aga ...... esence of maternal antibodies.
@en
Novel vaccine formulations aga ...... esence of maternal antibodies.
@nl
prefLabel
Novel vaccine formulations aga ...... esence of maternal antibodies.
@en
Novel vaccine formulations aga ...... esence of maternal antibodies.
@nl
P2093
P1433
P1476
Novel vaccine formulations aga ...... esence of maternal antibodies.
@en
P2093
Aleksandra Gracia
Andrew A Potter
Jill van Kessel
Lorne A Babiuk
Monika Polewicz
Srinivas Garlapati
Stacy Strom
Volker Gerdts
P304
P356
10.1016/J.VACCINE.2013.05.008
P407
P577
2013-05-15T00:00:00Z